Zentalis Pharmaceuticals, Inc. announced that the first patient has been dosed in Part 2A of the DENALI Phase 2 clinical trial, which evaluates the efficacy of azenosertib for patients with Cyclin E1+ ...
Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...
Four attractively valued dividend paying mid-cap regional banks. These research candidates include high-yield, moderate yield, and above-average growth opportunities. Not every regional bank suffered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results